Estimating cumulative pathway effects on risk for age-related macular degeneration using mixed linear models

BackgroundAge-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the elderly in developed countries and typically affects more than 10 % of individuals over age 80. AMD has a large genetic component, with heritability estimated to be between 45 % and 70 %. Numerous variants have been identified and implicate various molecular mechanisms and pathways for AMD pathogenesis but those variants only explain a portion of AMD’s heritability. The goal of our study was to estimate the cumulative genetic contribution of common variants on AMD risk for multiple pathways related to the etiology of AMD, including angiogenesis, antioxidant activity, apoptotic signaling, complement activation, inflammatory response, response to nicotine, oxidative phosphorylation, and the tricarboxylic acid cycle. While these mechanisms have been associated with AMD in literature, the overall extent of the contribution to AMD risk for each is unknown.MethodsIn a case–control dataset with 1,813 individuals genotyped for over 600,000 SNPs we used Genome-wide Complex Trait Analysis (GCTA) to estimate the proportion of AMD risk explained by SNPs in genes associated with each pathway. SNPs within a 50 kb region flanking each gene were also assessed, as well as more distant, putatively regulatory SNPs, based on DNaseI hypersensitivity data from ocular tissue in the ENCODE project.ResultsWe found that 19 previously associated AMD risk SNPs contributed to 13.3 % of the risk for AMD in our dataset, while the remaining genotyped SNPs contributed to 36.7 % of AMD risk. Adjusting for the 19 risk SNPs, the complement activation and inflammatory response pathways still explained a statistically significant proportion of additional risk for AMD (9.8 % and 17.9 %, respectively), with other pathways showing no significant effects (0.3 % – 4.4 %).DiscussionOur results show that SNPs associated with complement activation and inflammation significantly contribute to AMD risk, separately from the risk explained by the 19 known risk SNPs. We found that SNPs within 50 kb regions flanking genes explained additional risk beyond genic SNPs, suggesting a potential regulatory role, but that more distant SNPs explained less than 0.5 % additional risk for each pathway.ConclusionsFrom these analyses we find that the impact of complement SNPs on risk for AMD extends beyond the established genome-wide significant SNPs.

[1]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[2]  A. Ramé [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[3]  BMC Bioinformatics , 2005 .

[4]  William S Bush,et al.  Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. , 2010, American journal of human genetics.

[5]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[6]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[7]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[8]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[9]  R J Glynn,et al.  A prospective study of cigarette smoking and risk of age-related macular degeneration in men. , 1996, JAMA.

[10]  P. Zipfel,et al.  The role of complement in AMD. , 2010, Advances in experimental medicine and biology.

[11]  A E Braley,et al.  Dystrophy of the macula. , 1966, American journal of ophthalmology.

[12]  N. Orr,et al.  Neovascular Age-Related Macular Degeneration Risk Based on CFH, LOC387715/HTRA1, and Smoking , 2007, PLoS medicine.

[13]  J L Haines,et al.  Association of the apolipoprotein E gene with age-related macular degeneration: possible effect modification by family history, age, and gender. , 2000, Molecular vision.

[14]  Jason H. Moore,et al.  Pathway analysis of genomic data: concepts, methods, and prospects for future development. , 2012, Trends in genetics : TIG.

[15]  P. Jong Prevalence of age-related macular degeneration in the United States. , 2004 .

[16]  Johanna M Seddon,et al.  The genetics of age-related macular degeneration: a review of progress to date. , 2006, Survey of ophthalmology.

[17]  J. Haines,et al.  Genetic Factors in Nonsmokers with Age‐Related Macular Degeneration Revealed Through Genome‐Wide Gene‐Environment Interaction Analysis , 2011, Annals of human genetics.

[18]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[19]  E. Agrón,et al.  Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. , 2013, JAMA ophthalmology.

[20]  Gui-Shuang Ying,et al.  The role of apoptosis in age-related macular degeneration. , 2002, Archives of ophthalmology.

[21]  William Stafford Noble,et al.  Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays , 2006, Nature Methods.

[22]  Gabriëlle H S Buitendijk,et al.  Seven New Loci Associated with Age-Related Macular Degeneration , 2013, Nature Genetics.

[23]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[24]  J. Heier,et al.  Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments. , 2013, Ophthalmology.

[25]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[26]  P.T.V.M. de Jong,et al.  Mechanisms of disease: Age-related macular degeneration , 2006 .

[27]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[28]  Chen Zhao,et al.  mTOR pathway activation in age-related retinal disease , 2011, Aging.

[29]  Robert W. Massof,et al.  Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. , 2004, Archives of ophthalmology.

[30]  G. Abecasis,et al.  Age-related macular degeneration: genetics and biology coming together. , 2014, Annual review of genomics and human genetics.

[31]  Mary Goldman,et al.  The UCSC Genome Browser database: update 2011 , 2010, Nucleic Acids Res..

[32]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[33]  David Haussler,et al.  The UCSC Genome Browser database: update 2010 , 2009, Nucleic Acids Res..

[34]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[35]  Terrence S. Furey,et al.  The UCSC Genome Browser Database: update 2006 , 2005, Nucleic Acids Res..

[36]  Johanna M Seddon,et al.  The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. , 2005, Archives of ophthalmology.

[37]  Nicolas Leveziel,et al.  ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration. , 2011, American journal of ophthalmology.

[38]  Lincoln Stein,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Res..

[39]  P. Bernstein,et al.  Factorial analysis of tricarboxylic acid cycle intermediates for optimization of zeaxanthin production from Flavobacterium multivorum , 2004, Journal of applied microbiology.

[40]  Margaret A. Pericak-Vance,et al.  Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration , 2010, Proceedings of the National Academy of Sciences.

[41]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.